We use cookies for a better user experience. Read our Privacy Policy

I Agree

Red Biotechnology Market

Red Biotechnology Market (Application: Biopharmaceutical Production, Gene Therapy, Pharmacogenomics, and Genetic Testing) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Red Biotechnology Market Outlook 2031

  • The global red biotechnology market was valued at US$ 357.2 Bn in 2021
  • The global market is projected to grow at a CAGR of 5.6% from 2022 to 2031
  • The global red biotechnology market is anticipated to reach more than US$ 609.6 Bn by the end of 2031

Analysts’ Viewpoint on Red Biotechnology Market Scenario

Introduction of recombinant DNA (rDNA) methods marked the beginning of the biotechnology era. Innumerable studies and tests on the potential of biotechnology to improve health have been undertaken since. Development of biotechnology has made it possible to design innovative therapeutic medications for effective disease treatment. Usage of red biotechnology products in individualized medical therapies is likely to create lucrative opportunities for market players. Rise in prevalence of chronic diseases, rapid growth of the biopharmaceutical sector, and increase in healthcare expenditure are expected to propel the global red biotechnology market in the next few years. Additionally, increase in technological advancements in the treatment of chronic diseases and rich pipeline of novel therapeutic compounds are likely to augment the global market.

Red Biotechnology Market

Red Biotechnology Market Introduction

Supporting sectors in the biotech industry, such as health services, are growing steadily. Investors are particularly interested in healthcare start-ups in the biotechnology field. Artificial intelligence (AI) is being used in various new ways. For instance, it has been used to progressively alter biotechnology research projects, as it helps reduce the cost and time taken to develop life-saving medications.

Stem cell research, which is one of the game-changing red biotechnology applications, is advancing at a heightened pace. It focuses on designing highly individualized therapies using a patient's own cells. Similarly, genetic engineering involves altering a patient's genetic makeup to find certain spots of interest. Steps are being taken to investigate and incorporate biotechnology into the development of individualized medical care. The implications of cloud-based technology, AI, and increasing focus on R&D have given businesses in the biotechnology sector a competitive edge.

Request a sample to get extensive insights into the Red Biotechnology Market

Rise in Prevalence of Chronic Diseases Driving Global Red Biotechnology Market

The need for innovative drug molecules for effective disease treatment is expected to be driven by the increase in number of chronic and rare diseases globally. The WHO estimates that there are between 6,000 and 8,000 rare diseases, and over 80% of these are hereditary abnormalities. Hence, rise in incidence and prevalence of chronic and rare diseases and increase in need for diagnostics and treatments for quick and effective disease management are likely to drive the global red biotechnology market during the forecast period.

Rapid Expansion of Bio-pharmaceutical Industry to Propel Global Market

Increase in R&D efforts, rise in number of patients suffering from diseases such as cancer, and rapid expansion of health care and pharmaceutical sectors in developed and emerging markets are projected to augment the global red biotechnology market during the forecast period. According to India Brand Equity Foundation, the country’s biotechnology sector, which includes bio-pharmaceuticals, bio-services, bio-agriculture, bio-industrial, and bioinformatics, is expected to advance at a CAGR of 30% to reach US$ 100.0 Bn by 2025.

Request a custom report on Red Biotechnology Market

Increase in Demand for Biologics and Technological Advancements to Fuel Biopharmaceutical Production Segment

In terms of application, the global red biotechnology market has been classified into biopharmaceutical production, gene therapy, pharmacogenomics, and genetic testing. The biopharmaceutical production segment is likely to account for major share of the global market during the forecast period. Increase in demand for biologics and technological advancements are projected to drive the segment in the next few years. Furthermore, rise in disease prevalence in emerging and developed markets, and increase in healthcare spending are expected to boost the biopharmaceutical production segment.

Surge in Demand for Biologics for Treatment of Chronic Illnesses Propelling Biopharmaceutical Industry Segment

Based on end-user, the global red biotechnology market has been divided into biopharmaceutical industry, CMO & CRO, research institutes, and others. The biopharmaceutical industry segment is expected to account for the major share of the global market during the forecast period. The segment is likely to be driven by the rise in demand for biologics in the treatment of chronic diseases and increase in clinical trial activities. Surge in adoption of expansion strategies by well-established players is also projected to augment the biopharmaceutical industry segment.

Regional Outlook of Global Red Biotechnology Market

North America dominated the global red biotechnology market in 2021, led by the increase in adoption of red biotechnology, new product approvals, rise in mergers & acquisitions, and surge in healthcare expenditure.

Asia Pacific is expected to offer lucrative opportunities to leading players in the red biotechnology market during the forecast period. Growth in product approvals from regional governing authorities, rise in number of CMOs & CROs, and surge in investment by large biopharmaceutical manufacturers are the major drivers anticipated to propel the red biotechnology market in Asia Pacific in the near future.

Europe also held vital share of the global market in 2021. The market in the region is expected to be driven by research activities, increase in patient population, expansion of the healthcare infrastructure, and rise in number of clinical studies and product approvals.

Analysis of Key Players in Global Red Biotechnology Market

The global red biotechnology market is fragmented, with significant presence of large-scale players. Leading players operating in the global red biotechnology market are Pfizer, Inc., Biogen, Inc., Amgen, Inc., AstraZeneca plc, Gilead Sciences, Inc., Celgene Corporation (Bristol-Myers Squibb Company), F. Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. These players are adopting growth strategies such as new product development, product launches, product approval, agreement, partnerships, and mergers to increase their market share.

Key Developments in Global Red Biotechnology Market

  • On August 5, 2022, the U.S. FDA approved MYFEMBREE, a once-daily treatment for the management of moderate to severe pain associated with endometriosis. It is developed by Myovant Sciences and Pfizer. With a maximum treatment time of 24 months, MYFEMBREE provides an efficient once-daily therapy option for the control of moderate to severe endometriosis-related pain.
  • On June 6, 2022, Amgen's RIABNI (RITUXIMAB-ARRX), a biosimilar to RITUXAN (RITUXIMAB), received the FDA approval for adults with moderate to severe rheumatoid arthritis. Based on the totality of the evidence such as comparative analytical, non-clinical, and clinical data, RIABNI, a CD20-directed cytolytic antibody, was shown to be substantially comparable to Rituxan (rituximab), with no clinically relevant changes in safety or effectiveness.

Each of the players has been profiled in the red biotechnology market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Red Biotechnology Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 357.2 Bn

Market Forecast Value in 2031

More than US$ 609.6 Bn

Growth Rate (CAGR) 2022-2031

5.6%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Application
    • Biopharmaceutical Production
    • Gene Therapy
    • Pharmacogenomics
    • Genetic Testing
  • End-user
    • Biopharmaceutical Industry
    • CMO & CRO
    • Research Institutes
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Biogen, Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Gilead Sciences, Inc.
  • Celgene Corporation (Bristol-Myers Squibb Company)
  • F. Hoffmann-La Roche, Ltd.
  • Merck KGaA
  • Bruker
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global red biotechnology market in 2021?

The global red biotechnology market was valued at US$ 357.2 Bn in 2021

How big will be the global red biotechnology market in 2031?

The global red biotechnology market is projected to reach more than US$ 609.6 Bn by 2031

What was the CAGR of the global red biotechnology market from 2017 to 2021?

The global red biotechnology market grew at a CAGR of 3.6% from 2017 to 2021

What will be the CAGR of the global red biotechnology market during the forecast period (2022–2031)?

The global red biotechnology market is anticipated to grow at a CAGR of 5.6% from 2022 to 2031

What was the market share of the leading segment of the global red biotechnology market?

The biopharmaceutical industry segment held around 42% share of the global red biotechnology market in 2021

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global red biotechnology market during the forecast period.

Who are the prominent players in the global red biotechnology market?

Prominent players in the global red biotechnology market are Pfizer, Inc., Biogen, Inc., Amgen, Inc., AstraZeneca plc, Gilead Sciences, Inc., Celgene Corporation (Bristol-Myers Squibb Company), F. Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceutical, Company Limited.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Red Biotechnology Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Red Biotechnology Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Reimbursement Scenario by Region/globally

    5.3. Key Industry Events (merger & acquisitions)

    5.4. Covid-19 Impact Analysis

6. Global Red Biotechnology Market Analysis and Forecast, by Application

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Application, 2017–2031

        6.3.1. Biopharmaceutical Production

        6.3.2. Pharmacogenomics

        6.3.3. Gene Therapy

        6.3.4. Genetic Testing

    6.4. Market Attractiveness Analysis, by Application

7. Global Red Biotechnology Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2031

        7.3.1. Biopharmaceutical Industry

        7.3.2. CMO & CRO

        7.3.3. Research Institutes

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by End-user

8. Global Red Biotechnology Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Red Biotechnology Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Application, 2017–2031

        9.2.1. Biopharmaceutical Production

        9.2.2. Pharmacogenomics

        9.2.3. Gene Therapy

        9.2.4. Genetic Testing

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Biopharmaceutical Industry

        9.3.2. CMO & CRO

        9.3.3. Research Institutes

        9.3.4. Others

    9.4. Market Value Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Application

        9.5.2. By End-user

        9.5.3. By Country

10. Europe Red Biotechnology Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Application, 2017–2031

        10.2.1. Biopharmaceutical Production

        10.2.2. Pharmacogenomics

        10.2.3. Gene Therapy

        10.2.4. Genetic Testing

    10.3. Market Value Forecast, by End-user, 2017–2031

        10.3.1. Biopharmaceutical Industry

        10.3.2. CMO & CRO

        10.3.3. Research Institutes

        10.3.4. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Application

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Red Biotechnology Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Application, 2017–2031

        11.2.1. Biopharmaceutical Production

        11.2.2. Pharmacogenomics

        11.2.3. Gene Therapy

        11.2.4. Genetic Testing

    11.3. Market Value Forecast, by End-user, 2017–2031

        11.3.1. Biopharmaceutical Industry

        11.3.2. CMO & CRO

        11.3.3. Research Institutes

        11.3.4. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. India

        11.4.3. Japan

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Application

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Red Biotechnology Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Application, 2017–2031

        12.2.1. Biopharmaceutical Production

        12.2.2. Pharmacogenomics

        12.2.3. Gene Therapy

        12.2.4. Genetic Testing

    12.3. Market Value Forecast, by End-user, 2017–2031

        12.3.1. Biopharmaceutical Industry

        12.3.2. CMO & CRO

        12.3.3. Research Institutes

        12.3.4. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Application

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Red Biotechnology Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Application, 2017–2031

        13.2.1. Biopharmaceutical Production

        13.2.2. Pharmacogenomics

        13.2.3. Gene Therapy

        13.2.4. Genetic Testing

    13.3. Market Value Forecast, by End-user, 2017–2031

        13.3.1. Biopharmaceutical Industry

        13.3.2. CMO & CRO

        13.3.3. Research Institutes

        13.3.4. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Application

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2021

    14.3. Company Profiles

        14.3.1. Pfizer, Inc.

            14.3.1.1. Company Overview

            14.3.1.2. Financial Overview

            14.3.1.3. Product Portfolio

            14.3.1.4. Business Strategies

            14.3.1.5. Recent Developments

        14.3.2. Biogen, Inc.

            14.3.2.1. Company Overview

            14.3.2.2. Financial Overview

            14.3.2.3. Product Portfolio

            14.3.2.4. Business Strategies

            14.3.2.5. Recent Developments

        14.3.3. Amgen, Inc.

            14.3.3.1. Company Overview

            14.3.3.2. Financial Overview

            14.3.3.3. Product Portfolio

            14.3.3.4. Business Strategies

            14.3.3.5. Recent Developments

        14.3.4. AstraZeneca plc

            14.3.4.1. Company Overview

            14.3.4.2. Financial Overview

            14.3.4.3. Product Portfolio

            14.3.4.4. Business Strategies

            14.3.4.5. Recent Developments

        14.3.5. Gilead Sciences, Inc.

            14.3.5.1. Company Overview

            14.3.5.2. Financial Overview

            14.3.5.3. Product Portfolio

            14.3.5.4. Business Strategies

            14.3.5.5. Recent Developments

        14.3.6. Celgene Corporation (Bristol-Myers Squibb Company)

            14.3.6.1. Company Overview

            14.3.6.2. Financial Overview

            14.3.6.3. Product Portfolio

            14.3.6.4. Business Strategies

            14.3.6.5. Recent Developments

        14.3.7. F. Hoffmann-La Roche, Ltd.

            14.3.7.1. Company Overview

            14.3.7.2. Financial Overview

            14.3.7.3. Product Portfolio

            14.3.7.4. Business Strategies

            14.3.7.5. Recent Developments

        14.3.8. Merck KGaA

            14.3.8.1. Company Overview

            14.3.8.2. Financial Overview

            14.3.8.3. Product Portfolio

            14.3.8.4. Business Strategies

            14.3.8.5. Recent Developments

        14.3.9. Regeneron Pharmaceuticals, Inc.

            14.3.9.1. Company Overview

            14.3.9.2. Financial Overview

            14.3.9.3. Product Portfolio

            14.3.9.4. Business Strategies

            14.3.9.5. Recent Developments

        14.3.10. Takeda Pharmaceutical Company Limited

            14.3.10.1. Company Overview

            14.3.10.2. Financial Overview

            14.3.10.3. Product Portfolio

            14.3.10.4. Business Strategies

            14.3.10.5. Recent Developments

List of Tables

Table 01: Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031

Table 02: Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 03: Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region, 2022–2031

Table 04: North America Red Biotechnology Market Value (US$ Bn) Forecast, by Country, 2022–2031

Table 05: North America Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031

Table 06: North America Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 07: Europe Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 08: Europe Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031

Table 09: Europe Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 10: Asia Pacific Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 11: Asia Pacific Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031

Table 12: Asia Pacific Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 13: Latin America Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 14: Latin America Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031

Table 15: Latin America Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 16: Middle East & Africa Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 17: Middle East & Africa Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031

Table 18: Middle East & Africa Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031

List of Figures

Figure 01: Global Red Biotechnology Market Value (US$ Bn) Forecast, 2022–2031

Figure 02: Global Red Biotechnology Market Value Share (%), by Application, 2021

Figure 03: Global Red Biotechnology Market Value Share (%), by End-user, 2021

Figure 04: Global Red Biotechnology Market Value Share (%), by Region, 2021

Figure 05: Global Red Biotechnology Market Value Share (%), by Application, 2021 and 2031

Figure 06: Global Red Biotechnology Market Attractiveness Analysis, by Application, 2021–2031

Figure 07: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Biopharmaceutical Production, 2022–2031

Figure 08: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Gene Therapy, 2022–2031

Figure 09: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Pharmacogenomics, 2022–2031

Figure 10: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Genetic Testing, 2022–2031

Figure 11: Global Red Biotechnology Market Value Share Analysis, by End-user, 2021–2031

Figure 12: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Biopharmaceutical Industry, 2022–2031

Figure 13: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by CMO & CRO, 2022–2031

Figure 14: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Research Institutes, 2022–2031

Figure 15: Global Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%), by Others, 2022–2031

Figure 16: Global Red Biotechnology Market Attractiveness Analysis, by End-user, 2021–2031

Figure 17: Global Red Biotechnology Market Value Share Analysis, by Region, 2021 and 2031

Figure 18: Global Red Biotechnology Market Attractiveness Analysis, by Region, 2021–2031

Figure 19: North America Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 20: North America Red Biotechnology Market Value Share Analysis, by Country, 2021 and 2031

Figure 21: North America Red Biotechnology Market Attractiveness Analysis, by Country, 2021–2031

Figure 22: North America Red Biotechnology Market Value Share (%), by Application, 2021 and 2031

Figure 23: North America Red Biotechnology Market Attractiveness Analysis, by Application, 2021–2031

Figure 24: North America Red Biotechnology Market Value Share Analysis, by End-user, 2021–2031

Figure 25: North America Red Biotechnology Market Attractiveness Analysis, by End-user, 2021–2031

Figure 26: Europe Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 27: Europe Red Biotechnology Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 28: Europe Red Biotechnology Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 29: Europe Red Biotechnology Market Value Share (%), by Application, 2021 and 2031

Figure 30: Europe Red Biotechnology Market Attractiveness Analysis, by Application, 2021–2031

Figure 31: Europe Red Biotechnology Market Value Share Analysis, by End-user, 2022–2031

Figure 32: Europe Red Biotechnology Market Attractiveness Analysis, by End-user, 2022–2031

Figure 33: Asia Pacific Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 34: Asia Pacific Red Biotechnology Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 35: Asia Pacific Red Biotechnology Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 36: Asia Pacific Red Biotechnology Market Value Share (%), by Application, 2021 and 2031

Figure 37: Asia Pacific Red Biotechnology Market Attractiveness Analysis, by Application, 2021–2031

Figure 38: Asia Pacific Red Biotechnology Market Value Share Analysis, by End-user, 2022–2031

Figure 39: Asia Pacific Red Biotechnology Market Attractiveness Analysis, by End-user, 2021–2031

Figure 40: Latin America Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 41: Latin America Red Biotechnology Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 42: Latin America Red Biotechnology Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 43: Latin America Red Biotechnology Market Value Share (%), by Application, 2021 and 2031

Figure 44: Latin America Red Biotechnology Market Attractiveness Analysis, by Application, 2021–2031

Figure 45: Latin America Red Biotechnology Market Value Share Analysis, by End-user, 2022–2031

Figure 46: Latin America Red Biotechnology Market Attractiveness Analysis, by End-user, 2021–2031

Figure 47: Middle East & Africa Red Biotechnology Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 48: Middle East & Africa Red Biotechnology Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 49: Middle East & Africa Red Biotechnology Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 50: Middle East & Africa Red Biotechnology Market Value Share (%), by Application, 2021 and 2031

Figure 51: Middle East & Africa Red Biotechnology Market Attractiveness Analysis, by Application, 2021–2031

Figure 52: Middle East & Africa Red Biotechnology Market Value Share Analysis, by End-user, 2022–2031

Figure 53: Middle East & Africa Red Biotechnology Market Attractiveness Analysis, by End-user, 2021–2031

Figure 54: Global Red Biotechnology Market Share, by Company, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

629

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved